Published Studies Related to Glipizide and Metformin (Glipizide / Metformin)
Well-designed clinical trials related to Glipizide and Metformin (Glipizide / Metformin)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. [2007.03]
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. [2006]
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. [2005.05]
Well-designed clinical trials possibly related to Glipizide and Metformin (Glipizide / Metformin)
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. [2007.09]
Sitagliptin: a novel drug for the treatment of type 2 diabetes. [2007.09]
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]
Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. [2005.05]
Other research related to Glipizide and Metformin (Glipizide / Metformin)
[Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry] [2007.10]
Other possibly related research studies
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. [2006.07]
Toxicology case of the month: oral hypoglycaemic overdose. [2006.07]
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. [2005]
Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. [2005]
Sitagliptin. [2007]
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes] [2008.02]
A comparative study of the glycemic control of various antidiabetic agents and the role of homocysteine in the therapy of type 2 diabetes mellitus. [2008.03]
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. [2008.06]
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. [2008.06]
Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. [2008.12]
Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. [2009.03]
|
